Yagna PR Jarajapu, M.Pharm., Ph.D.,
16 Sudro Hall
Neuropharmacology for Pharm.D students (PSCI 416).
Angiotensin converting enzyme-2 (ACE2)/Angiotensin-(1-7) System in Endothelial Progenitor Cells.
Role of Endothelial Progenitor Cells in Vascular Dysfunction in Diabetes.
2002 Ph.D. Glasgow Caledonian University, UK
1998 M.Sc. University of Strathclyde, UK
1993 M.Pharm. Andhra University, India
1990 B.Pharm Andhra University, India
1997 Academy of Commonwealth Universities (ACU) and Oversees
Development Administration (ODA) Shared Scholarship.
1991 University Grants Commission (UGC) Fellowship.
1991 Indian Drug Manufacturers Association (IDMA), G.P.Nair Award.
2008-2011 Asst. Instructor, Pharmacology & Therapeutics, University of Florida, Gainesville, FL.
2005-2007 Part-Time, Technology-Scientist, Danish MyoTechnology-USA, Inc.
2005-2007 Post-Doctoral Associate, Wake Forest University, Winston-Salem NC.
2002-2004 Post-Doctoral Associate, Pharmacology & Therapeutics, University of Florida, Gainesville, FL.
1995-1997 Sr. Pharmacologist, Dr. Reddy’s Research Foundation, Hyderabad, India.
2011 to date Member of American Association of Colleges of Pharmacy (AACP).
2007 to date Professional member of American Heart Association (AHA).
2002 to date Regular member of American Society of Pharmacology and
Experimental Therapeutics (ASPET).
2006-2011 Member of the Association for Research in Vision and
1998-2007 Regular member of the British Pharmacological Society (BPS).
1998-2004 Member of British Physiological Society.
1995-1997 Member of Indian Pharmacological Society (IPS).
Life member Indian Pharmaceutical Graduates Association (IPGA).
Jarajapu YP, Caballero S, Verma A, Nakagawa T, Lo MC, Li Q and Grant MB. (2011). Blockade of NADPH oxidase restores vasoreparative function in diabetic CD34+ cells. Invest Ophthalmol Vis Sci. 52(8):5093-5104.
Jarajapu YP and Grant MB. (2010). The promise of cell-based therapies for diabetic complications: challenges and solutions. Circ Res 106(5):854-869.
Bhatwadekar AD, Guerin EP, Jarajapu YP, et al. (2010). Transient inhibition of transforming growth factor-ß1 in human diabetic CD34+ cells enhances vascular reparative functions. Diabetes 59(8):2010-2019.
Katakam PV, Domoki F, Snipes JA, Busija AR, Jarajapu YP, and Busija DW. (2009). Impaired mitrochondria-dependent vasodilation in cerebral arteries of Zucker obese rats with insulin resistance. Am J Physiol Regul Integr Comp Phsyiol.
Kielczewski JL, Jarajapu YP, McFarland EL, et al. (2009). Insulin-like growth factor binding protein-3 mediates vascular repair by enhancing nitric oxide generation. Circ Res 105(9):897-905.
Ito I, Jarajapu YP, Grant MB and Knot HJ. (2006). Myogenic tone and reactivity of the rat ophthalmic artery in the acute exposure of high glucose and in a type II diabetic model. Invest Ophthalmol Vis Sci. 47(2):683-692.
Jarajapu YP and Knot HJ. (2005). Relative contribution of protein kinase C and Rho-kinase to myogenic tone in cerebral arteries in hypertension. Am J Physiol Heart Circ Phsyiol. 289(5):H1917-1922.
Follow this link for the full list of publications and citations http://www.ncbi.nlm.nih.gov/pubmed?term=yagna%20OR%20jarajapu
Christ GJ, Burmeister D, Vishwajit S, Jarajapu YP and Andersson K-E. Assessing the performance of tissue-engineered urological implants. In: Densdtedt J and Atala A, editors, Biomaterials and Tissue Engineering in Urology. Cambridge: Woodhead Publishing Limited. 2009:299-315.
Coats P, Jarajapu YP and Hillier C. Differential effects of critical limb ischaemia on endothelium-mediated responses in human resistance arteries. In: Vanhoutte PM, editor, EDHF 2000. London: Taylor and Francis. 2001:376-387.
Invited reviewer for the journals, Cardiovascular Research, Journal of Pharmacology and Experimental Therapeutics, European Journal of Pharmacology and Pharmacology & Therapeutics.